Immunotherapy

Immunotherapy - most related articles:

- Prostate cancer immunotherapy prolongs survival - 4.9
- GVAX cancer immunotherapy improves prostate cancer survival - 4.6
- Boosting immune response to destroy tumours - 3.8
- New approaches developed to treat food allergy sufferers - 2.7
- Immunotherapy with vaccine improves advanced melanoma - 2.4
- OPAL Therapy cost-effective method of treating HIV - 2.3

Immunotherapy articles

New technique extends cancer fighting cells' potency in melanoma patients
Researchers trained white blood cells to attack tumors tend to fade away quickly when injected into cancer patients.

Immunotherapy with vaccine improves advanced melanoma
A vaccine for one of the most lethal cancers, advanced melanoma, has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2, according to researchers from The University of Texas M. D. Anderson Cancer Center.

Prostate cancer immunotherapy prolongs survival
Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago.

Boosting immune response to destroy tumours
Researchers have discovered how to trigger an improved immune response to cancer that could be included in new clinical trials that use a patient's own cells to destroy tumours.

Prostate cancer vaccine Provenge prolongs survival
Dendreon Corporation (Nasdaq: DNDN) announced that the pivotal Phase 3 IMPACT study of PROVENGE (sipuleucel-T) in men with advanced prostate cancer met its primary endpoint of improving overall survival compared to a placebo control.

New treatment may cure food allergies
A team of scientists from across Europe are embarking on new research to develop a treatment for food allergy.

OPAL Therapy cost-effective method of treating HIV
Australian researchers have unveiled a new immunotherapy technique to help prevent the progression from HIV infection to AIDS. Details of the simple, cost-effective technique are published May 2nd in the open-access journal PLoS Pathogens.

GVAX cancer immunotherapy improves prostate cancer survival
Cell Genesys, Inc. (Nasdaq: CEGE) announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, has completed a pre-planned interim analysis and has recommended that the study continue, as GVAX cancer immunotherapy improves prostate cancer patients survival.

8 Immunotherapy articles listed above.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
0.92